DE69838417D1 - An caml bindender lymphozyteoberflächenrezeptor, nukleinsäuren die dafür kodieren und verfahren zur verwendung - Google Patents
An caml bindender lymphozyteoberflächenrezeptor, nukleinsäuren die dafür kodieren und verfahren zur verwendungInfo
- Publication number
- DE69838417D1 DE69838417D1 DE69838417T DE69838417T DE69838417D1 DE 69838417 D1 DE69838417 D1 DE 69838417D1 DE 69838417 T DE69838417 T DE 69838417T DE 69838417 T DE69838417 T DE 69838417T DE 69838417 D1 DE69838417 D1 DE 69838417D1
- Authority
- DE
- Germany
- Prior art keywords
- caml
- nucleic acids
- surface receptor
- lymphocyte surface
- acids coded
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/810,572 US5969102A (en) | 1997-03-03 | 1997-03-03 | Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof |
US810572 | 1997-03-03 | ||
PCT/US1998/004270 WO1998039361A1 (en) | 1997-03-03 | 1998-03-03 | A lymphocyte surface receptor that binds caml, nucleic acids encoding the same and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69838417D1 true DE69838417D1 (de) | 2007-10-25 |
DE69838417T2 DE69838417T2 (de) | 2008-05-29 |
Family
ID=25204137
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69838417T Expired - Lifetime DE69838417T2 (de) | 1997-03-03 | 1998-03-03 | An caml bindender lymphozyteoberflächenrezeptor, nukleinsäuren die dafür kodieren und verfahren zur verwendung |
Country Status (11)
Country | Link |
---|---|
US (7) | US5969102A (de) |
EP (3) | EP1632500B1 (de) |
JP (1) | JP3594975B2 (de) |
AT (1) | ATE373012T1 (de) |
AU (1) | AU732119B2 (de) |
CA (1) | CA2284078C (de) |
DE (1) | DE69838417T2 (de) |
DK (1) | DK0964874T3 (de) |
ES (2) | ES2292201T3 (de) |
PT (1) | PT964874E (de) |
WO (1) | WO1998039361A1 (de) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA95960B (en) * | 1994-03-14 | 1995-10-10 | Genetics Inst | Use of interleukin-12 antagonists in the treatment of autoimmune diseases |
US6706264B1 (en) | 1994-03-14 | 2004-03-16 | Genetics Institute, Llc | Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y |
US6812327B1 (en) * | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
US8212004B2 (en) * | 1999-03-02 | 2012-07-03 | Human Genome Sciences, Inc. | Neutrokine-alpha fusion proteins |
US5969102A (en) * | 1997-03-03 | 1999-10-19 | St. Jude Children's Research Hospital | Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof |
US7488590B2 (en) | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
GB9828628D0 (en) | 1998-12-23 | 1999-02-17 | Glaxo Group Ltd | Novel ligand |
US20060067933A1 (en) * | 1999-01-07 | 2006-03-30 | Gross Jane A | Soluble receptor BR43x2 and methods of using |
ES2329254T3 (es) * | 1999-01-07 | 2009-11-24 | Zymogenetics, Inc. | Usos terapeuticos de receptores solubles de br43x2. |
US7833529B1 (en) | 1999-01-07 | 2010-11-16 | Zymogenetics, Inc. | Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor |
AU2005200008B2 (en) * | 1999-01-07 | 2008-03-06 | Zymogenetics, Inc. | Soluble receptor BR43x2 and methods of using |
US20030095967A1 (en) * | 1999-01-25 | 2003-05-22 | Mackay Fabienne | BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders |
DE60004635T2 (de) * | 1999-01-25 | 2004-06-09 | Biogen, Inc., Cambridge | Baff, dessen inhibitoren und dessen verwendung zur modulierung der b-zell-antwort |
US20050100548A1 (en) * | 2001-07-24 | 2005-05-12 | Biogen Idec Ma Inc. | BAFF, inhibitors thereof and their use in the modulation of B-cell response |
WO2000058362A1 (en) * | 1999-03-26 | 2000-10-05 | Human Genome Sciences, Inc. | Neutrokine-alpha binding proteins and methods based thereon |
US20030022233A1 (en) * | 1999-04-30 | 2003-01-30 | Raymond G. Goodwin | Methods of use of the taci/taci-l interaction |
BRPI0013391B8 (pt) | 1999-08-17 | 2021-05-25 | Apotech R&D S A | uso de polipeptídeos bcma na preparação de uma composição farmacêutica para tratar uma doença autoimune ou um distúrbio linfoproliferativo de célula b |
UA74798C2 (uk) * | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
WO2001085782A2 (en) * | 2000-02-11 | 2001-11-15 | Amgen Inc. | Fusion receptor from tnf family |
DK1255558T3 (da) * | 2000-02-16 | 2006-10-23 | Genentech Inc | Anti-april antistoffer og hybridomaceller |
US6969519B2 (en) * | 2000-03-10 | 2005-11-29 | Human Genome Sciences, Inc. | Methods of using an agonistic antibody human tumor necrosis factor receptor (TR17) |
LT2857516T (lt) | 2000-04-11 | 2017-09-11 | Genentech, Inc. | Multivalentiniai antikūnai ir jų panaudojimas |
US20040013674A1 (en) * | 2001-04-27 | 2004-01-22 | Christine Ambrose | Taci as an anti-tumor agent |
AU5392001A (en) * | 2000-04-27 | 2001-11-07 | Biogen Inc | Taci as an anti-tumor agent |
EP1746106A3 (de) * | 2000-04-27 | 2007-03-14 | Biogen Idec MA Inc. | Verwendung von TACI als Antitumormittel |
WO2001087979A2 (en) * | 2000-05-12 | 2001-11-22 | Amgen Inc. | Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci |
CA2413160A1 (en) | 2000-06-15 | 2001-12-20 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
US7879328B2 (en) * | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
CA2407910C (en) | 2000-06-16 | 2013-03-12 | Steven M. Ruben | Antibodies that immunospecifically bind to blys |
WO2002004626A1 (fr) * | 2000-07-07 | 2002-01-17 | Eisai Co., Ltd. | Gene de synthese de la paroi des cellules fongiques |
DK1303293T3 (da) | 2000-07-27 | 2009-03-30 | Genentech Inc | Sekventiel indgivelse af CPT-11 og APO-2L-polypeptid |
WO2002016411A2 (en) * | 2000-08-18 | 2002-02-28 | Human Genome Sciences, Inc. | Binding polypeptides and methods based thereon |
UA83458C2 (uk) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf) |
WO2002046231A2 (en) * | 2000-12-07 | 2002-06-13 | The University Of British Columbia | Caml-binding peptides |
EP2301971A1 (de) * | 2001-02-20 | 2011-03-30 | ZymoGenetics, L.L.C. | Antikörper, die sowohl BCMA als auch TACI binden |
PT1385882E (pt) * | 2001-05-11 | 2008-01-11 | Amgen Inc | Péptidos e moléculas relacionadas que se ligam a tall- 1 |
EP1436003B3 (de) | 2001-05-24 | 2012-03-14 | ZymoGenetics, Inc. | Taci-immunoglobulin-fusionsproteine |
PT2087908T (pt) | 2001-06-26 | 2018-07-16 | Amgen Inc | Anticorpos contra opgl |
DE10131922A1 (de) * | 2001-07-02 | 2003-01-30 | Brahms Ag | Verwendung des Calcineurin B Homologen Proteins (CHP) für die Diagnose und Therapie von Entzündungserkrankungen und Sepsis |
EP2192130A1 (de) | 2001-07-03 | 2010-06-02 | Genentech, Inc. | Humane DR4-Antikörper und deren Anwendungen |
ATE443131T1 (de) * | 2001-07-10 | 2009-10-15 | Biogen Idec Inc | Hemmung des apoptoseprozesses und verbesserung der zelleistung |
JP2005510208A (ja) * | 2001-08-03 | 2005-04-21 | ジェネンテック・インコーポレーテッド | TACIs及びBR3ポリペプチドとその用途 |
US6551615B1 (en) * | 2001-10-18 | 2003-04-22 | M/S. Strides Arcolab Limited | Dexibuprofen-containing soft gelatin capsules and process for preparing the same |
US20080267965A1 (en) * | 2002-02-21 | 2008-10-30 | Kalled Susan L | Use of Bcma as an Immunoregulatory Agent |
US20040038303A1 (en) * | 2002-04-08 | 2004-02-26 | Unger Gretchen M. | Biologic modulations with nanoparticles |
US8025873B2 (en) * | 2002-06-20 | 2011-09-27 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
US6890725B2 (en) * | 2002-07-23 | 2005-05-10 | Rigel Pharmaceuticals, Inc. | Modulators of B-lymphocyte activation, myosin-1F compositions and methods of use |
WO2004011611A2 (en) * | 2002-07-25 | 2004-02-05 | Genentech, Inc. | Taci antibodies and uses thereof |
EP1558278B1 (de) * | 2002-10-11 | 2009-09-02 | ZymoGenetics, Inc. | Herstellung von homotrimeren fusionsproteinen |
US7700317B2 (en) | 2003-03-28 | 2010-04-20 | Biogen Idec Ma Inc. | Truncated baff receptors |
US20050163775A1 (en) * | 2003-06-05 | 2005-07-28 | Genentech, Inc. | Combination therapy for B cell disorders |
PT1631313E (pt) * | 2003-06-05 | 2015-07-02 | Genentech Inc | Terapêutica de combinação para distúrbios de células b |
US7211407B2 (en) * | 2003-07-15 | 2007-05-01 | Chan Test, Inc. | High throughput assay systems and methods for identifying agents that alter surface expression of integral membrane proteins |
AU2004315198A1 (en) * | 2004-01-29 | 2005-08-18 | Genentech, Inc. | Variants of the extracellular domain of BCMA and uses thereof |
US7381794B2 (en) | 2004-03-08 | 2008-06-03 | Zymogenetics, Inc. | Dimeric fusion proteins and materials and methods for producing them |
US20080181886A1 (en) * | 2004-11-04 | 2008-07-31 | Genentech, Inc. | Polypeptides That Bind Baff And/Or April |
AU2006209237B2 (en) * | 2005-01-28 | 2010-06-24 | Biogen Ma Inc. | Use of BAFF to treat Th2-mediated conditions |
WO2007019573A2 (en) * | 2005-08-09 | 2007-02-15 | Zymogenetics, Inc. | Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules |
KR20080056714A (ko) * | 2005-08-09 | 2008-06-23 | 지모제넥틱스, 인코포레이티드 | TACI―Ig 융합 분자를 사용하여 B―세포 악성종양을치료하는 방법 |
US9168286B2 (en) * | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
EP3037544A1 (de) * | 2005-10-13 | 2016-06-29 | Human Genome Sciences, Inc. | Verfahren und zusammensetzung zur verwendung bei der behandlung von systemisch lupus erythematosus patienten mit autoantikörper-positiven leiden |
PE20070684A1 (es) | 2005-11-14 | 2007-08-06 | Amgen Inc | MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP |
AU2006318539B2 (en) * | 2005-11-23 | 2012-09-13 | Genentech, Inc. | Methods and compositions related to B cell assays |
WO2007123765A2 (en) | 2006-03-31 | 2007-11-01 | Human Genome Sciences Inc. | Neutrokine-alpha and neutrokine-alpha splice variant |
EP2035028A2 (de) * | 2006-05-15 | 2009-03-18 | Ares Trading S.A. | Verfahren zur behandlung von autoimmunerkrankungen mittels taci-ig-fusionsmolekül |
MX2009002013A (es) * | 2006-08-28 | 2009-03-09 | Ares Trading Sa | Proceso para la purificacion de proteinas de fusion fc. |
HUE045898T2 (hu) | 2006-08-28 | 2020-01-28 | Ares Trading Sa | Eljárás Fc-t tartalmazó proteinek tisztítására |
WO2008090217A1 (en) | 2007-01-26 | 2008-07-31 | Merck Serono S.A. | Purification of fc-tact fusion proteins using the oilbody technology |
AU2008312406B2 (en) | 2007-10-16 | 2014-03-06 | Ares Trading S.A. | Combination of BLyS inhibition and anti-CD 20 agents for treatment of autoimmune disease |
US20110014190A1 (en) * | 2009-02-12 | 2011-01-20 | Human Genome Sciences, Inc. | Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance |
WO2011109280A1 (en) | 2010-03-05 | 2011-09-09 | Lerner Research Institute | Methods and compositions to treat immune-mediated disorders |
US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
JOP20140087B1 (ar) | 2013-03-13 | 2021-08-17 | Amgen Inc | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها |
CN110612119A (zh) | 2017-02-07 | 2019-12-24 | 西雅图儿童医院(Dba西雅图儿童研究所) | 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂 |
WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
CA3089051A1 (en) | 2018-01-22 | 2019-07-25 | Endocyte, Inc. | Methods of use for car t cells |
IL297980A (en) | 2020-05-08 | 2023-01-01 | Alpine Immune Sciences Inc | Immunomodulatory proteins that inhibit april and baff and methods of using them |
EP4265269A1 (de) * | 2020-12-16 | 2023-10-25 | Good T Cells, Inc. | Verwendung von taci protein |
EP4292603A1 (de) | 2021-08-10 | 2023-12-20 | RemeGen Co., Ltd. | Verfahren zur behandlung von iga-nephropathie mit taci-fc-fusionsprotein |
CN117203242A (zh) | 2021-09-30 | 2023-12-08 | 荣昌生物制药(烟台)股份有限公司 | 用TACI-Fc融合蛋白治疗干燥综合征的方法 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
NL7807532A (nl) | 1978-07-13 | 1980-01-15 | Akzo Nv | Metaal-immunotest. |
NL8000173A (nl) | 1980-01-11 | 1981-08-03 | Akzo Nv | Toepassing van in water dispergeerbare, hydrofobe kleurstoffen als label in immunochemische testen. |
US4650764A (en) | 1983-04-12 | 1987-03-17 | Wisconsin Alumni Research Foundation | Helper cell |
US4703017C1 (en) | 1984-02-14 | 2001-12-04 | Becton Dickinson Co | Solid phase assay with visual readout |
US4751181A (en) * | 1984-12-31 | 1988-06-14 | Duke University | Methods and compositions useful in the diagnosis and treatment of autoimmune diseases |
US4631211A (en) | 1985-03-25 | 1986-12-23 | Scripps Clinic & Research Foundation | Means for sequential solid phase organic synthesis and methods using the same |
CA1338860C (en) | 1987-04-13 | 1997-01-21 | Peter Parker | Radiolabelling of proteins |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
JPH0664061B2 (ja) | 1987-02-27 | 1994-08-22 | イーストマン コダック カンパニー | 免疫反応性試薬、その製造法及び免疫反応性種を測定するためのその用途 |
EP0280559B1 (de) | 1987-02-27 | 1993-10-20 | EASTMAN KODAK COMPANY (a New Jersey corporation) | Agglutinationsimmunotest und Satz zur Bestimmung einer mehrwertigen Immunspezies unter Verwendung einer gepufferten Salzwasch-Lösung |
US4857453A (en) | 1987-04-07 | 1989-08-15 | Syntex (U.S.A.) Inc. | Immunoassay device |
EP1248112A3 (de) | 1987-04-27 | 2004-08-25 | Inverness Medical Switzerland GmbH | Immunochromatographische Spezifischebindungsassayvorrichtung |
US4980289A (en) | 1987-04-27 | 1990-12-25 | Wisconsin Alumni Research Foundation | Promoter deficient retroviral vector |
DE3856559T2 (de) | 1987-05-21 | 2004-04-29 | Micromet Ag | Multifunktionelle Proteine mit vorbestimmter Zielsetzung |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5010175A (en) | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
IL92124A (en) | 1988-10-28 | 1996-10-31 | Sidney Pestka | Recombinant proteins modified to contain post-phosphorylation that do not occur in nature |
US5124263A (en) | 1989-01-12 | 1992-06-23 | Wisconsin Alumni Research Foundation | Recombination resistant retroviral helper cell and products produced thereby |
US5354844A (en) | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
US5139749A (en) | 1990-06-22 | 1992-08-18 | Tas, Inc. | Fluidized calcining process |
WO1992010591A1 (en) | 1990-12-14 | 1992-06-25 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
EP0573608A1 (de) | 1991-02-07 | 1993-12-15 | Molecumetics, Ltd. | Konformationseingeschränkte mimetika für beta-schleifen und beta-bögen und diese enthaltende peptide |
ES2204921T3 (es) | 1993-05-27 | 2004-05-01 | Selectide Corporation | Bibliotecas de fase solida codificadas, segregadas topologicamente. |
JPH09501055A (ja) | 1993-07-30 | 1997-02-04 | ユニバーシティ オブ メディシン アンド デンティストリー オブ ニュージャージー | 初代リンパ球への効率的遺伝子転移 |
US5650550A (en) * | 1993-10-01 | 1997-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Mutant mice having a deficit of functional estrogen receptors |
CA2187818A1 (en) | 1994-04-15 | 1995-10-26 | Robert W. Overell | Gene delivery fusion proteins |
US5523227A (en) * | 1994-06-17 | 1996-06-04 | The Board Of Trustees Of The Leland Stanford Junior Univ. | DNA encoding calcium-signal modulating cyclophilin ligand |
ES2292172T3 (es) * | 1994-12-15 | 2008-03-01 | Yeda Research And Development Co., Ltd. | Moduladores de la funcion de los receptores fas/apo1. |
US5837544A (en) | 1995-02-02 | 1998-11-17 | Cell Genesys, Inc. | Method of inducing a cell to proliferate using a chimeric receptor comprising janus kinase |
US5712149A (en) | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
US6103521A (en) | 1995-02-06 | 2000-08-15 | Cell Genesys, Inc. | Multispecific chimeric receptors |
US5969102A (en) | 1997-03-03 | 1999-10-19 | St. Jude Children's Research Hospital | Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof |
US6685728B2 (en) * | 2002-01-25 | 2004-02-03 | Stryker Endoscopy | Threaded suture anchor and method of use |
US9002545B2 (en) | 2011-01-07 | 2015-04-07 | Wabtec Holding Corp. | Data improvement system and method |
-
1997
- 1997-03-03 US US08/810,572 patent/US5969102A/en not_active Expired - Lifetime
-
1998
- 1998-03-03 AT AT98908948T patent/ATE373012T1/de active
- 1998-03-03 ES ES98908948T patent/ES2292201T3/es not_active Expired - Lifetime
- 1998-03-03 CA CA2284078A patent/CA2284078C/en not_active Expired - Lifetime
- 1998-03-03 DE DE69838417T patent/DE69838417T2/de not_active Expired - Lifetime
- 1998-03-03 AU AU66854/98A patent/AU732119B2/en not_active Expired
- 1998-03-03 JP JP53877898A patent/JP3594975B2/ja not_active Expired - Lifetime
- 1998-03-03 WO PCT/US1998/004270 patent/WO1998039361A1/en active IP Right Grant
- 1998-03-03 EP EP05020384.3A patent/EP1632500B1/de not_active Expired - Lifetime
- 1998-03-03 ES ES05020384.3T patent/ES2552095T3/es not_active Expired - Lifetime
- 1998-03-03 EP EP10179571A patent/EP2292654A3/de not_active Withdrawn
- 1998-03-03 DK DK98908948T patent/DK0964874T3/da active
- 1998-03-03 PT PT98908948T patent/PT964874E/pt unknown
- 1998-03-03 EP EP98908948A patent/EP0964874B1/de not_active Expired - Lifetime
-
1999
- 1999-04-12 US US09/290,333 patent/US6316222B1/en not_active Expired - Lifetime
-
2001
- 2001-02-14 US US09/782,857 patent/US6500428B1/en not_active Expired - Lifetime
-
2002
- 2002-11-12 US US10/293,816 patent/US20030082173A1/en not_active Abandoned
-
2005
- 2005-03-14 US US11/079,418 patent/US20050183148A1/en not_active Abandoned
- 2005-12-23 US US11/318,156 patent/US7355005B2/en not_active Expired - Fee Related
-
2008
- 2008-02-07 US US12/027,720 patent/US20090226473A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2001518080A (ja) | 2001-10-09 |
ES2292201T3 (es) | 2008-03-01 |
EP1632500B1 (de) | 2015-08-05 |
ES2552095T3 (es) | 2015-11-25 |
EP1632500A2 (de) | 2006-03-08 |
EP2292654A3 (de) | 2012-07-25 |
EP2292654A2 (de) | 2011-03-09 |
US6316222B1 (en) | 2001-11-13 |
DK0964874T3 (da) | 2007-12-10 |
US20030082173A1 (en) | 2003-05-01 |
WO1998039361A1 (en) | 1998-09-11 |
US5969102A (en) | 1999-10-19 |
PT964874E (pt) | 2007-12-21 |
AU732119B2 (en) | 2001-04-12 |
EP0964874A1 (de) | 1999-12-22 |
JP3594975B2 (ja) | 2004-12-02 |
US20050183148A1 (en) | 2005-08-18 |
DE69838417T2 (de) | 2008-05-29 |
EP0964874B1 (de) | 2007-09-12 |
US6500428B1 (en) | 2002-12-31 |
US20060101529A1 (en) | 2006-05-11 |
US7355005B2 (en) | 2008-04-08 |
AU6685498A (en) | 1998-09-22 |
ATE373012T1 (de) | 2007-09-15 |
CA2284078C (en) | 2014-09-09 |
EP1632500A3 (de) | 2007-05-30 |
CA2284078A1 (en) | 1998-09-11 |
US20090226473A1 (en) | 2009-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69838417D1 (de) | An caml bindender lymphozyteoberflächenrezeptor, nukleinsäuren die dafür kodieren und verfahren zur verwendung | |
DE60043626D1 (de) | Verfahren zur therapeutischen Verwendung von löslichen rezeptoren BR43X2 | |
DE69508236T2 (de) | Verfahren zur herstellung von fluorierten olefinen und fluorkohlenwasserstoffen unter verwendung von fluoriertem olefin | |
DE69824693D1 (de) | Ruthenium-Metathesekatalysator und Verfahren zur Olefinmetathese unter Verwendung des Katalysators | |
FI961251A0 (fi) | Ihmisten metabotrooppiset glutamaattireseptorialatyypit(HMR4, HMR6, HMR7)ja niihin liittyvät DNA-yhdisteet | |
DE69835154D1 (de) | Verfahren zur Bestimmung von Analyten mittels Antigenen, die in Thermoplasten eingebettet sind | |
DE69723860D1 (de) | VERFAHREN ZUR BESTIMMUNG VON IgE | |
ATE217636T1 (de) | Verfahren zur gewinnung von insulinvorläufern mit korrekt verbundenen cystinbrücken | |
DE69518550D1 (de) | Verfahren zur bereitung von kohlenwasserstoffe | |
ZA200409776B (en) | Immunoadhesin comprising a glycoprotein VI domain | |
DE69000163D1 (de) | Verfahren zur gewinnung von fluessigen kohlenwasserstoffen und einrichtung zur ausfuehrung dieses verfahrens. | |
DE69602534T2 (de) | Verfahren zur verwendung von metallocenkatalysatoren | |
DE69822629D1 (de) | Verfahren zur gerüstisomerisierung von olefinen | |
DE69830556D1 (de) | Verfahren zur Bestimmung von glykosylierten Proteinen | |
ATE341633T1 (de) | Verfahren zur spaltung von fusionproteinen | |
DE69701322D1 (de) | Verfahren zur herstellung von alpha-olefinen | |
DE69703110D1 (de) | Verfahren zur vorschwefelung von kohlenwasserstoffumwandlungskatalysatoren | |
ATE156118T1 (de) | Verfahren zur herstellung von fibrinogen-rezeptor-antagonisten | |
DE69808040T2 (de) | Abwechselndes Verfahren zur Metathese von Olefinen | |
DE59505524D1 (de) | Verfahren zur carbonylierung von olefinen | |
ATE462721T1 (de) | Breit einsetzbares verfahren zur identifizierung von modulatoren von g-protein gekoppelten rezeptoren | |
WO2000011204A3 (en) | Homer interacting proteins | |
DE69706300T2 (de) | Verfahren zur vorschwefelung von kohlenwasserstoffumwandlungskatalysatoren | |
DE69501761T2 (de) | Verfahren zur katalytischen Hydration von Olefinen | |
DE69718171D1 (de) | Verfahren zur herstellung von diiod flourverbindungen unter verwendung von cf2i2 und olefinen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |